



## Alliance *for* Lupus Research

PREVENT. TREAT. CURE.

Since its founding, the *Alliance for Lupus Research (ALR)* has given more money to lupus research than any non-governmental agency in the world. To date, the ALR has committed nearly \$100 million to lupus research.

<b>OUR RESEARCH FUNDING MECHANISMS:</b>	
<b>Target Identification in Lupus Grant (TIL) Program</b>	Under our TIL grant program, investigators leverage a two-year, up-to-\$400,000 award to remove the barriers to new treatments and a possible cure. A third year of funding for up-to-\$200,000 may be granted following the submission of a non-competitive progress report. All lupus research funded under the TIL program is based on realizable goals for translation into therapeutic discovery programs – that is, research that can move quickly from the laboratory to the patient’s bedside.
<b>Pfizer’s Centers for Therapeutic Innovation (CTI)</b>	Alliance for Lupus Research (ALR) and Pfizer’s Centers for Therapeutic Innovation (CTI) are partnering to discover new therapies for patients living with lupus. As part of this first-of-its-kind collaboration in lupus, ALR and CTI are co-funding novel translational research projects primarily driven by leading academic medical centers within the CTI partner network. Grants are awarded up to two years for a maximum of \$500,000. CTI’s goal and that of the ALR in this partnership is the same – to provide new, targeted therapies to patients living with lupus.
<b>International SLE Genetics Initiative (SLEGEN)</b>	Launched in 2005, this special initiative is designed to accelerate the search for genes that put people at risk for developing systemic lupus erythematosus (SLE or lupus). The SLEGEN Initiative facilitates this by pooling patient samples collected from the International SLE Genetics Consortium, which includes many scientists working on the genetics of lupus. In 2011, the ALR funded a study that helped the SLEGEN Consortium to utilize the most advanced technology available, called the ImmunoChip, to more closely examine the genes that were identified by SLEGEN in the past.

If you have questions about any of the ALR’s grant mechanisms, please contact Diomaris Gonzalez, Director of Research Administration at [dgonzalez@alr.org](mailto:dgonzalez@alr.org) or 212-218-2840.

<b>Target Identification in Lupus (TIL)</b>			
<b><u>Investigator</u></b>	<b><u>Institution</u></b>	<b><u>State</u></b>	<b><u>Project Title</u></b>
<b>2015</b>			
Carroll, Michael, PhD	Children's Hospital Boston	MA	Investigating the Mechanisms of Lupus-associated CNS Dysfunction
Craft, Joseph, MD	Yale University	CT	Characterization and Function of CD4 T Cell Subsets in Lupus
Criswell, Lindsey, MD, MPH	University of California, San Francisco	CA	The contribution of epigenetics to SLE phenotype and outcome
Elkon, Keith, MD	University of Washington	WA	The cyclic GAMP Pathway in SLE
Fathman, Gary, MD	Stanford University	CA	Understanding the MoA of Low Dose IL-2 as a Potential Therapy for SLE
Fu, Shu Man, MD, PhD	University of Virginia	VA	IL-2 and IL-33 as Therapeutic Agents for Lupus Nephritis
Jarjour, Wael, MD	The Ohio State University	OH	Regulation of T Follicular Helper Cells in SLE by E3 Ubiquitin Ligase Cbl-b
Jefferies, Caroline, PhD	Cedars-Sinai Medical Center	CA	Estrogen-dependent microRNAs as potential targets for the treatment of SLE
Kontaridis, Maria, PhD	Beth Israel Deaconess Medical Center	MA	Role for SHP2 as a therapeutic target for systemic lupus erythematosus
Kosiewicz, Michele, PhD	University of Louisville Research Foundation, Inc.	KY	Sex and microbiota influence on immunoregulation and disease in BWF1 mice
Rothlin, Carla, PhD	Yale University	CT	Protein S: at the crossroads of thrombosis and inflammation in SLE
Stohl, William, MD, PhD	University of Southern California	CA	Therapeutic targeting of FcγRIIb on B cells in SLE
Tsao, Betty, PhD	University of California, Los Angeles	CA	Targeting IL-10 producing B cells in SLE
Xiao, Sheng, PhD	Brigham and Women's Hospital, Inc.	MA	Role of Tim-1 in kidneys during lupus
Yan, Nan, PhD	UT Southwestern Medical Center	TX	Glycans and glycosylation defects as novel targets in lupus
<b>2014</b>			
Alarcon-Riquelme, Marta E., MD, PhD	Fundacion Publica Andaluza Progreso Y Salud - Spain	-	Influence of BANK1 in the In Vivo Development of Lupus
Casali, Paolo, MD	University of Texas Health Science Center	TX	B cell histone modifications and non-coding RNA as targets in lupus therapy
Cohen, Philip, MD	Temple University	PA	Aggregated MAVS as a Disease Mechanism in SLE
Erickson, Loren D., PhD	University of Virginia	VA	Role of the BAFF receptor BCMA to control B cell homeostasis and tolerance
Jacob, Chaim Oscar, MD, PhD	University of Southern California	CA	Towards understanding the role of NCF2 in SLE
Lu, Theresa T., MD, PhD	The Hospital for Special Surgery	NY	Targeting a dendritic cell-stromal axis in lupus
Mohan, Chandra, MD, PhD	University of Houston	TX	Bradykinins in Lupus
Morel, Laurence, PhD	University of Florida	FL	High through-put screening to repurpose drugs for lupus
Roopenian, Derry, PhD	Jackson Laboratories	ME	therapeutics
Peterson, Erik Jon, MD	University of Minnesota - Twin Cities	MN	Targeting interferogenic signals regulated by SLE risk gene PTPN22
Rathmell, Jeffrey C., PhD	Duke University Medical Center	NC	Metabolism of Effector T cells as a Target in SLE
Sullivan, Kathleen, MD, PhD	The Children's Hospital of Philadelphia	PA	IRF1 decoy treatment
Wakeland, Edward K., PhD	UT Southwestern Medical Center	TX	Identifying Functional Variants that Underlie SLE Susceptibility
<b>2013</b>			
Davidson, Anne, MBBS	The Feinstein Institute for Medical Research	NY	Inhibition of IL-6 trans-signaling in SLE
Davis, Laurie, PhD	UT Southwestern Medical Center	TX	TREM-1 in Lupus Nephritis
Holers, Michael, MD	University of Colorado Denver, AMC and DC	CO	The CR2:C3d Receptor:Ligand Interaction as a Therapeutic Target in Lupus
Karin, Michael, PhD	The University of California, San Diego	CA	New Targets for Treatment of Glucocorticoid-resistant Lupus
Lin, Gang, PhD	Joan & Sanford I. Weill Medical College of Cornell University	NY	Immunoproteasome Selective Inhibitors for Lupus Treatment
Morel, Laurence, PhD	University of Florida	FL	CD4 T cell metabolism in SLE: Characterization and target identification
Perrino, Fred W., PhD	Wake Forest University Health Sciences	NC	Targeting DNA polynucleotides in Lupus
Stohl, William, MD PhD	University of Southern California	CA	The roles of the individual elements of the BAFF axis in murine SLE
Vilen, Barbara J., PhD	University of North Carolina at Chapel Hill	NC	The Role of Immune Complexes and BAFF in Promoting Atherosclerosis in Lupus

<b>Pfizer's Centers for Therapeutic Innovation (CTI)</b>	
Hospital for Special Surgery	NY
Children's Hospital Boston	MA

<b>SLEGEN 2015</b>	
ImmunoChip	NC